PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
MyNeuroNews,
Background We previously demonstrated that subcutaneous administration of PT320, a sustained-release (SR) form of exendin-4…